Alumis (ALMS) Cash from Investing Activities (2023 - 2025)
Alumis (ALMS) posted quarterly Cash from Investing Activities of $95.0 million for Q4 2025, up 206.99% year-over-year from $31.0 million in Q4 2024, and up 295.29% quarter-over-quarter from $24.0 million in Q3 2025.
Analysis
Alumis (ALMS) Cash from Investing Activities (2023 - 2025) Analysis & Trends
Alumis (ALMS) has reported Cash from Investing Activities for 3 consecutive years, with $95.0 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Cash from Investing Activities rose 206.99% year-over-year to $95.0 million; the TTM figure through Dec 2025 stood at $287.9 million (up 352.99% YoY), while the FY2025 annual figure was $287.9 million, up 352.99% from the prior year.
- Cash from Investing Activities advanced to $95.0 million in Q4 2025 per ALMS's latest filing, from $24.0 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $129.4 million in Q2 2025 and bottomed at -$93.2 million in Q3 2024.
- Historically, Cash from Investing Activities has averaged $17.8 million across 3 years, with a median of $15.8 million in 2023.
- On a YoY basis, Cash from Investing Activities climbed as much as 846.86% in 2024 and fell as far as 1330.06% in 2024.
- Alumis' Cash from Investing Activities stood at -$4.1 million in 2023, then surged by 846.86% to $31.0 million in 2024, then jumped by 206.99% to $95.0 million in 2025.
- Business Quant data shows ALMS's Cash from Investing Activities at $95.0 million in Q4 2025, $24.0 million in Q3 2025, and $129.4 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Alumis | 1.43 Bn | 924.11 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 95.01 Mn |
| Sep 30, 2025 | 24.04 Mn |
| Jun 30, 2025 | 129.40 Mn |
| Mar 31, 2025 | 39.43 Mn |
| Dec 31, 2024 | 30.95 Mn |
| Sep 30, 2024 | -93.19 Mn |
| Jun 30, 2024 | -32.74 Mn |
| Mar 31, 2024 | -18.81 Mn |
| Dec 31, 2023 | -4.14 Mn |
| Sep 30, 2023 | 7.58 Mn |